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As the authors note, the familywise error rate (FWER) is used rather often, whereas the 
per-family error rate (PFER) is not. Is this as it should be? It would seem that no 
universal answer is possible, as context determines which is more appropriate in any 
given application. In the general scenario of testing the benefit of an intervention, one 
might ideally want an error rate that aligns with the decision for benefit. In most cases the 
FWER does this pretty well, while allowing one to identify those endpoints for which 
benefit exists. The PFER does not seem to have any advantage over the FWER in this 
general testing scenario. Perhaps in some other scenarios the PFER might have some 
reasonable role. 
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Introduction 
As Berger (2004) notes, the alpha level should be selected strategically, based on 
the ramifications of committing a Type I error relative to a Type II error. The 
entire testing framework becomes more complicated when dealing with multiple 
hypothesis tests, and in this case various circumstances must be taken into 
account. Apart from choosing the proper alpha level for the specific situation, one 
must also define (prospectively) what constitutes a win (so to speak). Is it enough 
to find statistical significance on any one endpoint? Or do we instead combine the 
results in some way to obtain an overall finding? 
The familywise Type-I error rate (FWER) is the probability of at least one 
Type I error in a family of hypotheses occurring, and is used rather often. The 
TROENDLE ET AL. 
39 
per-family Type I error rate (PFER) is the sum of probabilities of Type I errors in 
the family for all hypotheses, and is almost never used in practice (Frane, 2015). 
When performing multiple hypothesis tests, various circumstances must be 
taken into account. Apart from choosing the proper alpha level for the specific 
situation (preferably strategically, rather than based on the one size fits all  
precedent of 0.05), there is a risk that a Type I (false positive) or Type II (false 
negative) error may occur. The familywise Type-I error rate (FWER), the 
probability of at least one Type I error in a family of hypotheses occurring, is used 
rather often. Meanwhile, the per-family Type I error rate (PFER), the sum of 
probabilities of Type I errors in the family for all hypotheses, is almost 
completely ignored (Frane, 2015). Does the PFER deserve as much attention as 
the FWER receives? We do not attempt any general answer to this question, but, 
instead, focus on one specific application. For the commonly encountered 
scenario of testing the benefit of an intervention with several possible endpoints, 
we think there is a good reason why PFER is not used. 
As the author (Frane, 2015) states, committing numerous Type I errors 
simultaneously is worse than committing only one, with FWER unable to 
differentiate between creating one Type I error and multiple Type I errors in a 
family of hypotheses. We suggest that the choice between controlling the FWER 
or the PFER should be based on the specific situation. The FWER works well for 
the commonly encountered scenario of testing an intervention with several 
possible endpoints of interest. The PFER does not appear to have any advantage 
over the FWER in this scenario, but perhaps in some other scenarios it might. The 
purpose of this response is not to determine which error rate is superior to the 
other, but how to establish which error rate should be controlled based on a 
testing situation. We first consider the scenario of testing an intervention for 
benefit due to any of several endpoints and then discuss the choice of alpha level.  
Tests of an intervention with multiple endpoints of interest 
Consider a study designed to test whether an intervention or exposure is beneficial 
or detrimental to patient health, compared to some comparison condition. Suppose 
that benefit can be measured by using any of several endpoints. This is quite a 
general scenario, which applies equally to clinical trials as well as to behavioral 
intervention studies or in fact to many observational studies. In this case, it is easy 
to see that control of the FWER is sufficient to guarantee that if any endpoint is 
identified as significant, and if biases can be suitably removed by the study design, 
then either any such endpoint is truly affected by the intervention or an unlikely 
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event has occurred. This is also true if the PFER is controlled. However, control 
of the PFER is more restrictive (less powerful) than control of the FWER. Thus, 
there is no reason to prefer the PFER to the FWER in this general scenario. 
An interesting observation about this scenario is that control of the FWER is 
not necessary to guarantee the type of concordance desired. One might consider 
testing an intersection hypothesis whose rejection corresponds with evidence of 
an intervention benefit. To make this clearer, suppose that there are two endpoints, 
and let H1 (H2) be the null hypothesis that the first (second) endpoint is unaffected 
by the intervention. If one would recommend the intervention if either endpoint is 
beneficial, then one really wants to claim benefit if either H1 or H2 are false. This 
argues for testing the intersection null hypothesis H0 = H1 ∩ H2. Rejection of this 
null hypothesis corresponds to benefit. This approach circumvents multiple 
comparison altogether as only a single hypothesis is tested. 
The downside to this approach is that rejection of H0 leaves one unable to 
conclude improvement on any specific endpoint. As Durkalski and Berger (2009) 
note, success on a composite endpoint leaves one “unable to determine which 
outcome is driving the claim”. The other caveat to this approach is one must 
decide how to test H0, which in general could be difficult. An adaptive testing 
approach could prove useful (Berger and Ivanova, 2002), but the usual solution 
for testing H0 involves rejecting if min(p1, p2) ≤ α/2, where p1 (p2) is the p-value 
for testing H1 (H2). With this solution, one is once again controlling the FWER, 
although in general such an approach could lead to more powerful testing 
procedures. This observation is a major reason why FWER is the predominantly 
used error rate for publications of confirmatory findings for studies that test an 
intervention. Bloch et al. (2001) describe one way of testing a single null 
hypothesis, although rejecting their null also allows one to conclude non-
inferiority on all endpoints. 
Choosing an alpha level 
Returning now to the strategic selection of the alpha level, we note that 
cancer therapy often involves both high risk and high reward. The promise of 
meaningful improvement is counterbalanced by the almost certain toxicity of the 
treatment which, in some cases, may have the potential to do more harm than 
good. That said, false positives and false negatives can both result in grave 
consequences, including illnesses left untreated, illnesses over-treated, and 
ultimately higher mortality rates for patients. So the calculation has to consider 
the relative harm likely caused by each type of error. 
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As one extreme example (following Berger, 2004), one may conduct a trial 
to determine if broccoli will prevent arthritis. If broccoli is found, rightfully or 
wrongfully, to prevent arthritis, then the result would simply be increased 
consumption of broccoli. Since broccoli is known to have other health benefits, 
and few (if any) drawbacks, this will still lead to substantial health benefits, 
regardless if it helps to treat the symptoms of arthritis. So here, a Type I error 
would not result in very much harm at all. Alpha can be set to a much larger level 
than the usual 0.05. Another example is Glucosamine and Chondroitin. Like 
broccoli, these substances have no known side effects and are known to be 
generally good for cartilage health. Despite no strong evidence of a benefit for 
sufferers of osteoarthritis pain, many people take Glucosamine and Chondroitin 
because of the low risk involved coupled with some possible benefit. Conversely, 
if an aggressive and highly toxic cancer treatment is found to be beneficial, then 
its increased use will incur additional costs and also result in toxicity, so the 
benefit should offset this risk, and we should be fairly certain that it does (Berger, 
2004). A Type I error in this case would result in severe consequences, so alpha 
should be small, 0.05 or perhaps even 0.01. These are simple examples, but the 
concept is that alpha should be carefully considered, and not just set at the usual 
level of 0.05 as a matter of course (Berger & Hsieh, 2005). 
References 
Berger, V. W. (2004). On the generation and ownership of alpha in medical 
studies. Controlled Clinical Trials, 25(6), 613-619. doi:10.1016/j.cct.2004.07.006 
Berger, V. W., Hsieh, G. (2005). Rethinking statistics: basing efficacy alpha 
levels on safety data in randomized trials. Israeli Journal of Emergency Medicine, 
5(3), 55-60. http://isrjem.org/IJEM_Aug_AlphaLevels_Proof.pdf 
Berger, V. W., Ivanova, A. (2002). Adaptive tests for ordered categorical 
data. Journal of Modern Applied Statistical Methods, 1(2), 269-280. 
http://digitalcommons.wayne.edu/jmasm/vol1/iss2/36/ 
Bloch, D. A., Lai, T. L., Tubert-Bitter, P. (2001). One-sided tests in clinical 
trials with multiple endpoints. Biometrics, 57(4), 1039-1047. 
doi:10.1111/j.0006-341X.2001.01039.x 
Durkalski, V., Berger, V. W. (2009). Re-formulating equivalence trials as 
superiority trials: the case of binary outcomes. Biometrical Journal, 51(1), 
185-192. doi:10.1002/bimj.200810499 
PER-FAMILY ERROR RATES: A RESPONSE 
42 
Frane, A. V. (2015). Are Per-Family Type I Error Rate Relevant in Social 
and Behavioral Science? Journal of Modern Applied Statistical Methods, 14(1). 
